These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29092728)

  • 1. Extensive gastric mucosal atrophy is a possible predictor of clinical effectiveness of acotiamide in patients with functional dyspepsia
.
    Miki A; Yamamoto T; Maruyama K; Nakamura N; Aoyagi H; Isono A; Abe K; Kita H
    Int J Clin Pharmacol Ther; 2017 Dec; 55(12):901-904. PubMed ID: 29092728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan.
    Yamawaki H; Futagami S; Kawagoe T; Maruki Y; Hashimoto S; Nagoya H; Sato H; Kodaka Y; Gudis K; Akamizu T; Sakamoto C; Iwakiri K
    Neurogastroenterol Motil; 2016 Jul; 28(7):1037-47. PubMed ID: 26920949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia.
    Nakamura K; Tomita T; Oshima T; Asano H; Yamasaki T; Okugawa T; Kondo T; Kono T; Tozawa K; Ohda Y; Fukui H; Kazuhito F; Hirota S; Watari J; Miwa H
    J Gastroenterol; 2017 May; 52(5):602-610. PubMed ID: 27639387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia.
    Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kawarai Lefor A; Yamamoto H
    J Med Invest; 2016; 63(3-4):230-5. PubMed ID: 27644564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography.
    Kusunoki H; Haruma K; Manabe N; Imamura H; Kamada T; Shiotani A; Hata J; Sugioka H; Saito Y; Kato H; Tack J
    Neurogastroenterol Motil; 2012 Jun; 24(6):540-5, e250-1. PubMed ID: 22385472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia.
    Tack J; Janssen P
    Expert Opin Investig Drugs; 2011 May; 20(5):701-12. PubMed ID: 21417958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to an acotiamide therapeutic regimen improves long-term outcomes in patients with functional dyspepsia.
    Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Miura Y; Lefor AK; Yamamoto H
    J Gastrointestin Liver Dis; 2017 Dec; 26(4):345-350. PubMed ID: 29253047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia.
    Suzuki H; Hibi T
    Neurogastroenterol Motil; 2010 Jun; 22(6):595-9. PubMed ID: 20553562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage.
    Matsueda K; Hongo M; Tack J; Aoki H; Saito Y; Kato H
    Neurogastroenterol Motil; 2010 Jun; 22(6):618-e173. PubMed ID: 20059698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Double-Blind, Pilot Study of the Effect of Famotidine on Acotiamide Treatment for Functional Dyspepsia.
    Hojo M; Nagahara A; Asaoka D; Takeda T; Izumi K; Matsumoto K; Ueyama H; Shimada Y; Matsumoto K; Nojiri S; Watanabe S
    Digestion; 2017; 96(1):5-12. PubMed ID: 28605740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging treatments in neurogastroenterology: Acotiamade, a novel treatment option for functional dyspepsia.
    Matsushita M; Masaoka T; Suzuki H
    Neurogastroenterol Motil; 2016 May; 28(5):631-8. PubMed ID: 26730749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial.
    Tack J; Pokrotnieks J; Urbonas G; Banciu C; Yakusevich V; Bunganic I; Törnblom H; Kleban Y; Eavis P; Tsuchikawa M; Miyagawa T
    Neurogastroenterol Motil; 2018 Jun; 30(6):e13284. PubMed ID: 29315999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: postprandial distress syndrome.
    Altan E; Masaoka T; Farré R; Tack J
    Expert Rev Gastroenterol Hepatol; 2012 Sep; 6(5):533-44. PubMed ID: 23061703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of acotiamide for the treatment of functional dyspepsia.
    Sun Y; Song G; McCallum RW
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1161-8. PubMed ID: 24881488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double-blind, placebo-controlled crossover study.
    Funaki Y; Ogasawara N; Kawamura Y; Yoshimine T; Tamura Y; Izawa S; Ebi M; Sasaki M; Kasugai K
    Neurogastroenterol Motil; 2020 Feb; 32(2):e13749. PubMed ID: 31612597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia.
    Tack J; Masclee A; Heading R; Berstad A; Piessevaux H; Popiela T; Vandenberghe A; Kato H
    Neurogastroenterol Motil; 2009 Mar; 21(3):272-80. PubMed ID: 19254354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing and Predictors of Recurrence of Dyspepsia Symptoms after Cessation of Acotiamide Therapy for Functional Dyspepsia: A Long-Term Observational Study.
    Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kobayashi Y; Miura Y; Lefor AK; Yamamoto H
    Digestion; 2020; 101(4):382-390. PubMed ID: 31063995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.
    Matsueda K; Hongo M; Tack J; Saito Y; Kato H
    Gut; 2012 Jun; 61(6):821-8. PubMed ID: 22157329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A long-term study of acotiamide in patients with functional dyspepsia: results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration.
    Matsueda K; Hongo M; Ushijima S; Akiho H
    Digestion; 2011; 84(4):261-8. PubMed ID: 21934307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach.
    Yoshii K; Hirayama M; Nakamura T; Toda R; Hasegawa J; Takei M; Mera Y; Kawabata Y
    J Pharm Sci; 2011 Nov; 100(11):4965-73. PubMed ID: 21630282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.